Advertisement

Omicron variant can partially evade Pfizer vaccine protection: study

Click to play video: 'Omicron COVID-19 variant can partially evade protection from Pfizer vaccine, South African study finds'
Omicron COVID-19 variant can partially evade protection from Pfizer vaccine, South African study finds
WATCH: The Omicron COVID-19 variant can partially evade protection from two doses of the Pfizer-BioNTech vaccine, according to new research from the Africa Health Research Institute in South Africa (AHRI). However, AHRI executive director Willem Hanekom said researchers believe the vaccine will still protect against severe illness and death – Dec 8, 2021

The Omicron variant of the coronavirus can partially evade the protection from Pfizer Inc and partner BioNTech’s COVID-19 vaccine, the research head of a laboratory at Africa Health Research Institute in South Africa said on Tuesday.

Still, the study showed that blood from people who had received two doses of the vaccine and had a prior infection were mostly able to neutralize the variant, suggesting that booster doses of the vaccine could help to fend off infection.

Alex Sigal, a professor at the Africa Health Research Institute, said on Twitter there was “a very large drop” in neutralization of the Omicron variant relative to an earlier strain of COVID-19.

The lab tested blood from 12 people who had been vaccinated with two doses of the Pfizer/BioNTech vaccine, according to a manuscript posted on the website for his lab. The preliminary data in the manuscript has not yet been peer-reviewed.

Story continues below advertisement

Blood from five out of six people who had been vaccinated as well as previously infected with COVID-19 still neutralized the Omicron variant, the manuscript said.

 

“These results are better than I expected. The more antibodies you got, the more chance you’ll be protected from Omicron,” Sigal said on Twitter.

He said the lab had not tested the variant against blood from people who had received a booster dose, because they are not available in South Africa yet.

Receive the latest medical news and health information delivered to you every Sunday.

Get weekly health news

Receive the latest medical news and health information delivered to you every Sunday.
By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy.

According to the manuscript, they observed a 41-fold decline in levels of neutralizing antibodies against the Omicron variant.

Sigal said on Twitter that figure is likely to be adjusted after his lab does more experiments.

While neutralizing antibodies are an indicator of the body’s immune response, scientists believe other kinds of cells such as B-cells and T-cells also are stimulated by the vaccines and help protect against the effects of coronavirus.

The Omicron variant, first detected in southern Africa last month, has triggered alarms globally of another surge in infections, with more than two dozen countries from Japan to the United States reporting cases.

Story continues below advertisement

The World Health Organization on Nov. 26 classified it as a “variant of concern” but said there was no evidence to support the need for new vaccines specifically designed to tackle the Omicron variant with its many mutations.

Click to play video: 'COVID-19: No plans to change rules surrounding use of ArriveCAN app for those without smartphones'
COVID-19: No plans to change rules surrounding use of ArriveCAN app for those without smartphones

There is not significant data yet on how vaccines from Moderna, Johnson & Johnson and other drugmakers hold up against the new variant. All the manufacturers, including Pfizer, are expected to release their own data within weeks.

BioNTech CEO Ugur Sahin told NBC News on Tuesday that the drugmaker has data coming on Wednesday or Thursday related to the new variant.

Top U.S. infectious disease expert Dr. Anthony Fauci said on Tuesday that preliminary evidence indicates that the Omicron variant of the coronavirus likely has a higher degree of transmissibility but is less severe.

Story continues below advertisement

He said the United States was doing its own tests to determine the protectiveness of the current vaccines against the variant and expects results sometime next week.

Umer Raffat, an analyst for Evercore ISI, cautioned against reading too much into a single study, noting that there has been significant variability in measuring declines in antibody levels in previous lab studies.

“Let’s wait for additional studies to draw a mosaic,” he said.

Sponsored content

AdChoices